Literature DB >> 25342652

Endovascular revascularization results in IMS III: intracranial ICA and M1 occlusions.

Thomas A Tomsick1, Sharon D Yeatts1, David S Liebeskind2, Janice Carrozzella3, Lydia Foster1, Mayank Goyal2, Ruediger von Kummer4, Michael D Hill5, Andrew M Demchuk6, Tudor Jovin4, Bernard Yan7, Osama O Zaidat8, Wouter Schonewille9, Stefan Engelter10, Renee Martin11, Pooja Khatri2, Judith Spilker12, Yuko Y Palesch12, Joseph P Broderick2.   

Abstract

BACKGROUND: Interventional Management of Stroke III did not show that combining IV recombinant tissue plasminogen activator (rt-PA) with endovascular therapies (EVTs) is better than IV rt-PA alone.
OBJECTIVE: To report efficacy and safety results for EVT of intracranial internal carotid artery (ICA) and middle cerebral artery trunk (M1) occlusion.
METHODS: Five revascularization methods for persistent occlusions after IV rt-PA treatment were evaluated for prespecified primary and secondary endpoints, after accounting for differences in key baselines variables using propensity scores. Revascularization was scored using the arterial occlusive lesion (AOL) and the modified Thrombolysis in Cerebral Ischemia (mTICI) scores.
RESULTS: EVT of 200 subjects with intracranial ICA or M1 occlusion resulted in 81.5% AOL 2-3 recanalization, in addition to 76% mTICI 2-3 and 42.5% mTICI 2b-3 reperfusion. Adverse events included symptomatic intracranial hemorrhage (SICH) (8.0%), vessel perforations (1.5%), and new emboli (14.9%). EVT techniques used were standard microcatheter n=51; EKOS n=14; Merci n=77; Penumbra n=39; Solitaire n=4; multiple n=15. Good clinical outcome was associated with both TICI 2-3 and TICI 2b-3 reperfusion. Neither modified Rankin scale (mRS) 0-2 (28.5%), nor 90-day mortality (28.5%), nor asymptomatic ICH (36.0%) differed among revascularization methods after propensity score adjustment for subjects with intracranial ICA or M1 occlusion.
CONCLUSIONS: Good clinical outcome was associated with good reperfusion for ICA and M1 occlusion. No significant differences in efficacy or safety among revascularization methods were demonstrated after adjustment. Lack of high-quality reperfusion, adverse events, and prolonged time to treatment contributed to lower-than-expected mRS 0-2 outcomes and study futility compared with IV rt-PA. TRIAL REGISTRATION NUMBER: NCT00359424. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

Entities:  

Keywords:  Device; Intervention; Stroke; Thrombectomy; Thrombolysis

Mesh:

Substances:

Year:  2014        PMID: 25342652     DOI: 10.1136/neurintsurg-2014-011318

Source DB:  PubMed          Journal:  J Neurointerv Surg        ISSN: 1759-8478            Impact factor:   5.836


  5 in total

1.  First pass effect vs multiple passes complete reperfusion: A retrospective study.

Authors:  Ameer E Hassan; Mahmoud Dibas; Amrou Sarraj; Sherief Ghozy; Amr Ehab El-Qushayri; Adam A Dmytriw; Wondwossen G Tekle
Journal:  Neuroradiol J       Date:  2021-08-31

2.  Relationship between the first pass effect and the platelet-lymphocyte ratio in acute ischemic stroke.

Authors:  Orkun Sarioglu; Ahmet Ergin Capar; Demet Funda Bas Sokmez; Pelin Topkaya; Umit Belet
Journal:  Interv Neuroradiol       Date:  2020-11-25       Impact factor: 1.764

Review 3.  Efficacy and safety of mechanical thrombectomy for M2 segment of middle cerebral artery: a systematic review and meta-analysis.

Authors:  Jian Wang; Jiacheng Qian; Lu Fan; Yujie Wang
Journal:  J Neurol       Date:  2020-01-22       Impact factor: 4.849

4.  Clot-based radiomics features predict first pass effect in acute ischemic stroke.

Authors:  Orkun Sarioglu; Fatma C Sarioglu; Ahmet E Capar; Demet Fb Sokmez; Berna D Mete; Umit Belet
Journal:  Interv Neuroradiol       Date:  2021-05-18       Impact factor: 1.764

Review 5.  Endovascular therapy for acute ischemic stroke: The standard of care.

Authors:  Ashutosh P Jadhav; Tudor G Jovin
Journal:  Brain Circ       Date:  2016-12-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.